Join IAG and WPD Pharmaceuticals’ Experts to Discuss the Potential of Advanced Imaging to Show Early Treatment Effects of Berubicin in Brain Cancer
Join Mariusz Olejniczak, CEO of WDP Pharmaceuticals, and Diana Dupont-Roettger, Chief Scientific Alliance Officer of IAG, during a live webinar to discuss how advanced imaging can show early treatment effects in brain cancer.
Bringing a novel glioblastoma multiforme (‘GBM’) therapy to the market requires a robust clinical trial that will assess the effectiveness of the potential treatment. The design and delivery of such trials is a challenge.
If you are interested in a replay, please reach out to email@example.com
About the Webinar:
WPD Pharmaceuticals (‘WPD’) is a biotechnology research and development company focused on developing drug candidates involved in targeted therapy for brain cancers. Its lead drug candidate, Berubicin, is proposed for the treatment of GBM, an aggressive and incurable form of brain cancer. www.wpdpharmaceuticals.com
IAG, Image Analysis Group (‘IAG’) is a leading medical imaging company and will work closely with WPD to provide critical imaging services, its proprietary platform DYNAMIKA and imaging data analysis to assess the effects of Berubicin in a phase II clinical trial in patients with GBM.
Advanced cancer therapies, such as WPD’s Berubicin treatment, often lead to pseudo-progression, a local tissue reaction resulting from immune cell infiltration, causing inflammation, tumor necrosis and oedema which are often misinterpreted as tumor growth on traditional MRIs.
Pseudo-progression is difficult to distinguish from disease progression using routine clinical radiographic assessments. This is where non-invasive methods are needed to enhance the understanding of complex neuro-pathologies.
Novel imaging strategies and artificial intelligence (‘AI’) driven imaging biomarkers can advance neuro-oncology clinical trials by providing deep analysis of disease progression and treatment response. They are most efficiently integrated in clinical trials when implemented using a cloud-platform, such as IAG’s DYNAMIKA, that combines central review of standard radiographic endpoints, such as Response Assessment in Neuro-Oncology (‘RANO’), as well as advanced imaging endpoints in a cost and time efficient fashion.
Register for this joint webinar from WPD and IAG to learn more about Berubicin and how the development of novel brain cancer therapies ca be advanced with the use of AI and efficient imaging data management.
Key discussion points:
- Increasing chances of success in brain chancer drug development with the use of modern trial infrastructure and advanced imaging.
- Selection of imaging biomarkers that go beyond conventional radiographic assessments and can identify pseudoprogression and treatment-related changes early.
- Enabling advanced imaging strategies in global multi-center clinical trials.
- De-risking clinical trials and accelerating drug development through efficient central imaging data management and centralized review.
About Mariusz Olejniczak:
Graduate of Biotechnology at the University of Life Sciences in Poznań. Experienced professional in medicinal products, medical devices, supplements and plant protection products R&D at every stage – from planning and scientific advice through supervision to the closure and finalization of the project. A founder of several start-ups in the e-health industry and a member of the board and supervisory board of several R&D companies. Author of the publication „Change of the product development model as an opportunity for the Polish pharmaceutical industry” (in Polish). Member of the editorial committee of the book „Clinical Trials” (in Polish). Lecturer in postgraduate study programs.
About Dr. Diana Dupont-Roettger:
Medical Computer Scientist by background with strong experience in novel imaging technologies, AI and imaging markers and their role in clinical trials. She advises biopharmaceutical companies on the strategic use of advanced imaging to evaluate mechanism of action, enable precision medicine and accelerate drug development in immuno-oncology and neuro-oncology indications.